Ads
related to: car t-cell therapy and multiple myeloma
Search results
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 3 hours agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...
Medical Moment: Car T-Cell Therapy
WNDU 16 South Bend· 3 days agoMedical experts call it a “breakthrough” and “gamechanger” when it comes to cancer treatment. “Immunotherapy has really come on as quite an advance in...
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of...
WROC Rochester· 6 days agoOn May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of...
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 7 days agoAnito-cel, which utilizes Arcellx’s novel D-Domain binder, is a BCMA CAR T-cell therapy, a type of...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Yucaipa News Mirror· 2 days agoExpanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 6 days agoKite, a Gilead Company, and Arcellx have announced plans to commence a Phase III clinical trial of...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 7 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple ...
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
BioPharma Dive via Yahoo Finance· 6 days agoInterim data surpassed expectations, iTeos said. Elsewhere, Acelyrin revealed chief executive...
Breakthrough therapies are saving lives, but can we afford them?
Medical Xpress· 3 days agoLast month, Stanford became the first hospital in the nation to use a new $515,000 cell therapy to...
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...
GuruFocus.com via Yahoo Finance· 6 days agoThe company also reported on its FT825 / ONO-8250 CAR T-cell therapy for solid tumors, with the first patient treated ...
